Get the SPI Wire

CADRENAL THERAPEUTICS, INC.

NASDAQ:CVKD
Annual Meeting

of Shareholders

MEETING DATE

09/24/2026
DEF 14A FILED
08/03/2026
PUBLISHED
08/03/2026 9:09 pm
TIME TO PUBLISH
08/05/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:CVKD· CUSIP 127636207 · CLASS common stock, $0.001 par value per share · CIK 0001937993

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

5
FOR
0
AGAINST
0
WITHHOLD
5
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Election of the Class I director named in the accompanying proxy statement to our Board of Directors, to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified
board
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The nominee has consented to serve if elected.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To ratify the appointment of WithumSmith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending on December 31, 2026.
auditor
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

The Audit Committee concluded the independent registered public accounting firm is independent from Cadrenal and its management.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve an amendment to the Company's 2022 Successor Equity Incentive Plan, as amended (the “2022 Plan”), in substantially the form attached to the accompanying proxy statement as Annex A, to increase the number of shares of the Company's Common Stock that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares (the “Plan Amendment Proposal”).
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

As of the Record Date, 264,587 shares remained available for future issuance under the 2022 Plan.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To approve, pursuant to Nasdaq Rule 5635(d), the issuance of up to 960,000 shares of the Company's Common Stock upon the exercise of Series C-1 warrants, which warrants were issued in connection with a private placement offering that closed on July 1, 2026 (the “Warrant Exercise Proposal”).
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Approval is required for the Series C-1 Warrants to become exercisable under Nasdaq Rule 5635(d).

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To approve an adjournment of the 2026 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Plan Amendment Proposal and/or the Warrant Exercise Proposal.
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states adjournment may permit further solicitation for the Plan Amendment Proposal and the Warrant Exercise Proposal.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

3d4fadf7201da77a2ccc1d8ca7f2553adb54cdfb5123962af3d8d00abedead4d

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates